Intellia’s “One-and-Done”: Why Mid-2026 is the Tipping Point for In Vivo Editing Gene Therapy Intellia’s “One-and-Done”: Why Mid-2026 is the Tipping Point for In Vivo
Intellia’s “One-and-Done”: Why Mid-2026 is the Tipping Point for In Vivo Editing Gene Therapy Intellia’s “One-and-Done”: Why Mid-2026 is the Tipping Point for In Vivo
The FDA’s real-time clinical trial announcement is the most structurally significant regulatory initiative since the Expedited IND proposal in March. For 60 years, clinical trial
Thursday delivered two of the quarter’s most consequential catalysts, and both landed exactly where the data said they would. Rhythm Pharmaceuticals secured FDA approval for
Flow cytometry leader schedules presentations at three major healthcare investment conferences Cytek Biosciences announced its participation in three prominent investor conferences: the UBS Precision Medicine